Nonlinear mixed‐effects model development and simulation using nlmixr and related R open‐source packages M Fidler, JJ Wilkins, R Hooijmaijers, TM Post, R Schoemaker, MN Trame, ... CPT: pharmacometrics & systems pharmacology 8 (9), 621-633, 2019 | 65 | 2019 |
Pharmacodynamic attainment of the synergism of meropenem and fosfomycin combination against Pseudomonas aeruginosa producing metallo-β-lactamase J Albiero, J Mazucheli, JPR Barros, MMA Szczerepa, SAB Nishiyama, ... Antimicrobial Agents and Chemotherapy 63 (6), 10.1128/aac. 00126-19, 2019 | 36 | 2019 |
Ranibizumab population pharmacokinetics and free VEGF pharmacodynamics in preterm infants with retinopathy of prematurity in the RAINBOW trial M Fidler, BW Fleck, A Stahl, N Marlow, JE Chastain, J Li, D Lepore, ... Translational Vision Science & Technology 9 (8), 43-43, 2020 | 35 | 2020 |
Flexible interaction model for complex interactions of multiple anesthetics M Fidler, SE Kern The Journal of the American Society of Anesthesiologists 105 (2), 286-296, 2006 | 35 | 2006 |
Effect of initial subcellular localization of progesterone receptor on import kinetics and transcriptional activity H Li, ML Fidler, CS Lim Molecular pharmaceutics 2 (6), 509-518, 2005 | 30 | 2005 |
RxODE: facilities for simulating from ODE-based models M Fidler, M Hallow, J Wilkins, W Wang R package version 1 (9), 2019 | 21 | 2019 |
nlmixr: Nonlinear mixed effects models in population pharmacokinetics and pharmacodynamics M Fidler, Y Xiong, R Schoemaker, J Wilkins, M Trame, T Post, W Wang R package version 2 (1), 2021 | 14 | 2021 |
Performance of the SAEM and FOCEI algorithms in the open‐source, nonlinear mixed effect modeling tool nlmixr R Schoemaker, M Fidler, C Laveille, JJ Wilkins, R Hooijmaijers, TM Post, ... CPT: Pharmacometrics & Systems Pharmacology 8 (12), 923-930, 2019 | 14 | 2019 |
R and nlmixr as a gateway between statistics and pharmacometrics M Fidler, R Hooijmaijers, R Schoemaker, JJ Wilkins, Y Xiong, W Wang CPT: Pharmacometrics & Systems Pharmacology 10 (4), 283, 2021 | 6 | 2021 |
nlmixr: Nonlinear Mixed Effects Models in Population Pharmacokinetics and Pharmacodynamics, 2018, r package version 1.0. 0-7 M Fidler, Y Xiong, R Schoemaker, J Wilkins, M Trame, T Post, W Wang | 6 | |
Projected 24-hour post-dose ocular itching scores post-treatment with olopatadine 0.7% versus 0.2% ML Fidler, A Ogundele, D Covert, R Sarangapani Journal of Pharmacokinetics and Pharmacodynamics 45, 593-605, 2018 | 4 | 2018 |
Modelling the interaction of propofol and remifentanil by means of an adaptive neuro fuzzy inference system (ANFIS): A-514 P Gambús, E Jensen, GM Palli, M Fidler, S Kern European Journal of Anaesthesiology| EJA 23, 134, 2006 | 3 | 2006 |
Package ‘RxODE’ M Hallow, ML Fidler, W Wang | 1 | 2017 |
Package ‘rxode2’ MML Fidler, M Hallow, W Wang, MW Wang | | 2024 |
Package ‘lbfgsb3c’ ML Fidler, JC Nash, C Zhu, R Byrd, J Nocedal, JL Morales | | 2024 |
Pharmacodynamic Model to Predict Ocular Itching Outcomes at 24 Hours Post-Treatment with Olopatadine (0.77% or 0.2%) ML Fidler, M Stat, A Narvekar, D Covert, R Sarangapani Journal of Allergy and Clinical Immunology 137 (2), AB257, 2016 | | 2016 |
A Model-Based Approach to Describe Olopatadine Itching in Ocular Allergy Patients for a CAC Study M Fidler, A Narvekar, R Sarangapani JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 41, S63-S64, 2014 | | 2014 |
A Model-based Approach to Support Once-a-day Formulation Development for Topically Administered Brinzolamide in Glaucoma Patients M Fidler, A Weber, R Sarangapani JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 40, S69-S70, 2013 | | 2013 |
Modeling interactions of low dose propfol and remifentanil: A-511 ML Fidler, PL Gambus, X Barba, EW Jensen, S Kern European Journal of Anaesthesiology| EJA 23, 133, 2006 | | 2006 |
Statistically testable parameter drug interaction modeling ML Fidler The University of Utah, 2006 | | 2006 |